Subscribe To

Price Alert Latest News Economic Calendar News

DCGO / DocGo Inc. (DCGO) Q4 2022 Earnings Call Transcript

Start Time: 17:00 January 1, 0000 5:41 PM ET DocGo Inc. (NASDAQ:DCGO ) Q4 2022 Earnings Conference Call March 13, 2023, 17:00 PM ET Company Participants Anthony Capone - CEO Norman Rosenberg - CFO Lee Bienstock - President and COO Mike Cole - Vice President, IR Conference Call Participants Richard Close - Canaccord Genuity Ryan MacDonald - Needham & Company David Grossman - Stifel Kieran Ryan - Deutsche Bank Operator Greetings, and welcome to the DocGo Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. Read More

Demo Live Account See Partner Details

Content Topics

Docgo

Inc

DCGO

2022

Earnings

Call

Transcript

dcgo

Stock

Posted: Mar 14 2023, 03:17

Author Name: Seeking Alpha

DCGO News

By The Motley Fool
September 18, 2023

Why DocGo Stock Plummeted by 7% on Monday

Its CEO resigned abruptly. His official bio stated falsely that he earned a master's degree in artificial intelligence (AI).

By Zacks Investment Research
September 15, 2023

DocGo Inc. (DCGO) Moves 6.8% Higher: Will This Strength Last?

DocGo Inc. (DCGO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the s

By Seeking Alpha
September 11, 2023

DocGo: Preventing Onboarding Problem From Turning Into A Crisis (Rating Downgrade)

DocGo was rewarded a no-bid contract by the NYC to provide medical care for the migrants, but this large contract is facing the risk of being revoked

By The Motley Fool
September 6, 2023

Why Shares of DocGo Are Slumping Wednesday

DocGo improved revenue in the second quarter. The company has added major contracts this year with EmblemHealth and Carnival Cruise Lines.

By Seeking Alpha
August 7, 2023

DocGo Inc. (DCGO) Q2 2023 Earnings Call Transcript

DocGo Inc. (NASDAQ:DCGO ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Corporate Participants Mike Cole - Director-Investor Relations An

By Zacks Investment Research
August 7, 2023

DocGo Inc. (DCGO) Reports Q2 Loss, Tops Revenue Estimates

DocGo Inc. (DCGO) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.07 p

By Zacks Investment Research
June 22, 2023

DocGo Inc. (DCGO) Surges 5.0%: Is This an Indication of Further Gains?

DocGo Inc. (DCGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for th

By Proactive Investors
May 12, 2023

DocGo's growth story keeps building, analysts say after mixed 1Q results

DocGo delivered what analysts at Canaccord called “mixed” results, but that was enough for the firm to reiterate its Buy rating and $13 price targ

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.